MALAT1, UCA1, CYTOR, HOTAIR, and GAS5 expressions were compared between breast cancer patients treated with tamoxifen alone (control) and those treated with tamoxifen plus NanoCurcumin (target group). This evidence concerns the gene CYTOR and breast carcinoma.